Stock SAN1 N SANOFI
Add to a list
To use this feature you must be a member
Log inSign up

Financials Sanofi Mexican S.E.

Equities

SAN1 N

FR0000120578

Pharmaceuticals

End-of-day quote Mexican S.E.
Other stock markets
 04:30:00 31/10/2023 am IST 		5-day change 1st Jan Change
1,629 MXN +1.22% Intraday chart for Sanofi -.--% -.--%
03/07 Bain, Cinven Said to Weigh Joint Bid for Sanofi's Consumer Health Division MT
03/07 Bain, Cinven Said to Weigh Joint Bid for Sanofi's Consumer Health Division MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 1,12,310 98,877 1,11,194 1,12,665 1,12,549 1,12,798 - -
Enterprise Value (EV) 1 1,28,816 1,07,666 1,21,177 1,19,102 1,20,342 1,19,759 1,15,326 1,10,820
P/E ratio 40 x 8.01 x 17.8 x 16.7 x 20.8 x 16.3 x 13.2 x 11.8 x
Yield 3.51% 4.07% 3.76% 3.96% 4.19% 4.29% 4.51% 4.94%
Capitalization / Revenue 3.11 x 2.74 x 2.94 x 2.62 x 2.61 x 2.43 x 2.27 x 2.14 x
EV / Revenue 3.57 x 2.99 x 3.21 x 2.77 x 2.79 x 2.59 x 2.32 x 2.1 x
EV / EBITDA 10.8 x 9.41 x 9.95 x 8.14 x 8.44 x 8.83 x 7.46 x 6.71 x
EV / FCF 21.7 x 15.4 x 15 x 14 x 14.2 x 16.4 x 12.7 x 11 x
FCF Yield 4.6% 6.48% 6.68% 7.12% 7.04% 6.09% 7.89% 9.1%
Price to Book 1.9 x 1.57 x 1.62 x 1.5 x 1.52 x 1.46 x 1.38 x 1.3 x
Nbr of stocks (in thousands) 12,53,178 12,56,375 12,55,293 12,54,060 12,53,891 12,50,117 - -
Reference price 2 89.62 78.70 88.58 89.84 89.76 90.23 90.23 90.23
Announcement Date 06/02/20 05/02/21 04/02/22 03/02/23 01/02/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 36,126 36,041 37,761 42,997 43,070 46,325 49,752 52,646
EBITDA 1 11,904 11,443 12,183 14,627 14,259 13,556 15,462 16,523
EBIT 1 9,758 9,762 10,714 13,040 12,670 12,144 13,782 14,916
Operating Margin 27.01% 27.09% 28.37% 30.33% 29.42% 26.21% 27.7% 28.33%
Earnings before Tax (EBT) 1 2,822 13,804 7,798 8,268 7,038 8,912 11,520 13,015
Net income 1 2,806 12,314 6,223 6,720 5,400 7,066 8,574 9,531
Net margin 7.77% 34.17% 16.48% 15.63% 12.54% 15.25% 17.23% 18.1%
EPS 2 2.240 9.820 4.970 5.370 4.310 5.549 6.819 7.669
Free Cash Flow 1 5,928 6,982 8,096 8,483 8,478 7,297 9,096 10,083
FCF margin 16.41% 19.37% 21.44% 19.73% 19.68% 15.75% 18.28% 19.15%
FCF Conversion (EBITDA) 49.8% 61.02% 66.45% 58% 59.46% 53.83% 58.83% 61.03%
FCF Conversion (Net income) 211.26% 56.7% 130.1% 126.24% 157% 103.27% 106.09% 105.8%
Dividend per Share 2 3.150 3.200 3.330 3.560 3.760 3.869 4.070 4.457
Announcement Date 06/02/20 05/02/21 04/02/22 03/02/23 01/02/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 10,432 9,994 9,674 10,116 12,482 10,725 10,222 9,965 11,964 10,919 10,464 10,413 12,974 11,878 10,805
EBITDA 1 3,952 2,623 3,426 3,163 4,931 3,107 3,703 3,087 4,460 3,009 3,192 2,706 4,328 2,628 -
EBIT 1 3,558 2,256 3,065 2,753 4,498 2,724 3,333 2,726 4,028 2,583 2,843 2,614 4,185 2,787 3,045
Operating Margin 34.11% 22.57% 31.68% 27.21% 36.04% 25.4% 32.61% 27.36% 33.67% 23.66% 27.17% 25.11% 32.26% 23.47% 28.18%
Earnings before Tax (EBT) 1 2,957 1,391 2,349 1,383 2,666 1,921 2,468 1,718 2,971 -249 1,310 2,011 3,684 2,137 -
Net income 1 2,317 1,131 2,009 1,175 2,076 1,460 1,995 1,435 2,525 -555 1,133 1,509 2,797 1,614 -
Net margin 22.21% 11.32% 20.77% 11.62% 16.63% 13.61% 19.52% 14.4% 21.1% -5.08% 10.83% 14.49% 21.56% 13.59% -
EPS 2 1.850 0.9000 1.610 0.9400 1.660 1.160 1.600 1.150 2.010 -0.4400 0.9100 1.201 2.219 1.280 -
Dividend per Share 2 - 3.330 - - - 3.560 - - - 3.760 0.9292 0.9289 0.9289 0.9289 0.9885
Announcement Date 28/10/21 04/02/22 28/04/22 28/07/22 28/10/22 03/02/23 27/04/23 28/07/23 27/10/23 01/02/24 25/04/24 - - - -
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 16,506 8,789 9,983 6,437 7,793 6,961 2,528 -
Net Cash position 1 - - - - - - - 1,978
Leverage (Debt/EBITDA) 1.387 x 0.7681 x 0.8194 x 0.4401 x 0.5465 x 0.5135 x 0.1635 x -
Free Cash Flow 1 5,928 6,982 8,096 8,483 8,478 7,297 9,096 10,083
ROE (net income / shareholders' equity) 12.7% 12.1% 12.5% 14.4% 13.6% 12.3% 13.5% 13.9%
ROA (Net income/ Total Assets) 2.5% 6.47% 5.3% 8.37% 4.27% 6.36% 7.22% 7.45%
Assets 1 1,12,072 1,90,442 1,17,327 80,248 1,26,517 1,11,039 1,18,735 1,27,854
Book Value Per Share 2 47.20 50.30 54.80 59.70 59.20 61.70 65.30 69.20
Cash Flow per Share 2 6.160 5.940 8.360 8.410 8.200 8.070 9.460 10.90
Capex 1 1,816 1,329 2,043 2,201 3,024 1,987 2,397 2,501
Capex / Sales 5.03% 3.69% 5.41% 5.12% 7.02% 4.29% 4.82% 4.75%
Announcement Date 06/02/20 05/02/21 04/02/22 03/02/23 01/02/24 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Sanofi

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
90.23 EUR
Average target price
108.1 EUR
Spread / Average Target
+19.79%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+54.07% 816B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+38.59% 634B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.05% 351B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.44% 323B
ABBVIE INC. Stock AbbVie Inc.
+5.72% 293B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.40% 238B
ROCHE HOLDING AG Stock Roche Holding AG
+0.61% 222B
NOVARTIS AG Stock Novartis AG
+13.24% 218B
AMGEN INC. Stock Amgen Inc.
+7.42% 167B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. SAN Stock
  4. SAN1 N Stock
  5. Financials Sanofi